Prospective Randomized Clinical Trial for Effect of Stellate Ganglion Block in Medically Refractory Ventricular Tachycardia

• Status: Unknown status
• Trial end date: 2019-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators will compare the effects of PSGB(percutaneous stellate ganglion block) in patients with recurrent sustained VT/VF in spite of appropriate medical therapy and cardio-version/ defibrillation after correction of underlying correctable factors with those without PSGB by prospective randomized trail. PSGB will be performed every 3 days by anesthesiology specialist after cardiologist's request, until the stabilization of VT/VF. We will compare the frequency and episode number of VT/VF, procedure related complication, acute and long-term mortality.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yonsei University
• Treatments: Anti-Arrhythmia Agents

Criteria

Inclusion Criteria:

• Patients agreement of consent

• AF patient age 20-85

• Patient are diagnosed Refractory Ventricular tachycardia

• Patients who have generated Refractory Ventricular tachycardia despite of defibrillation and drug therapy

• Patients with ICD have generated ICD shock or anti-tachycardia pacing despite of defibrillation and drug therapy

Exclusion Criteria:

• Patients who do not agree with study inclusion

• Patients who do not taken stellate ganglion block due to unstable hemodynamic status

• Patients have experienced major hemorrhagic complication

• Patients of the DNR status

• Patients with malignancy tumor, major neurogenic disease or gastrointestinal disease